End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
192.9 CNY | -2.50% | +3.13% | -40.71% |
22/04 | IRay Technology Company Limited Debuts at Hannover Messe 2024 | CI |
28/02 | IRay Technology's 2023 Profit Slides 3.5%, EPS Misses Estimates; Shares Fall 5% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.71% | 2.71B | C- | ||
-5.77% | 14.68B | - | ||
-12.92% | 2.44B | - | ||
-8.78% | 1.51B | - | - | |
-.--% | 1.12B | - | - | |
+40.66% | 518M | - | ||
+91.79% | 502M | B+ | ||
+11.68% | 239M | C | ||
+1.67% | 183M | - | ||
-.--% | 168M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 688301 Stock
- Ratings iRay Technology Company Limited